Dr. Melinda Elliott is the Chief Medical Officer (CMO) of Prolacta Bioscience. Since joining Prolacta in 2016, she has served as the voice of the patient, working to ensure that the needs of premature infants are being articulated and that relevant treatment and product opportunities are identified. She is also a board-certified neonatologist with over 30 years of experience and has held professional and clinical positions with the Pediatrix Medical Group, The Johns Hopkins Hospital, Union Memorial Hospital, Franklin Square Hospital Center, and The Herman & Walter Samuelson Children's Hospital at Sinai in Baltimore.
Dr. Elliott has committed her career to the care of vulnerable, premature infants and has researched the benefits of an Exclusive Human Milk Diet (EHMD) for extremely low birth weight premature infants in the neonatal intensive care unit (NICU). She has investigated breastfeeding practices of mothers of very low birth weight infants, and her clinical research is published in academic journals. An experienced neonatologist, educator, mentor, and leader in neonatal intensive care, Dr. Elliott earned her Doctor of Medicine degree from West Virginia University School of Medicine. She trained and taught extensively at the University of Florida including residency training in pediatrics, a faculty position as chief resident in pediatrics, and fellowship training in neonatal-perinatal medicine and has been a champion for babies since the inception of her medical career.
